Psychiatric Digital Biomarkers - Global Strategic Business Report

The global market for Psychiatric Digital Biomarkers was estimated at US$612.5 Million in 2024 and is projected to reach US$2.2 Billion by 2030, growing at a CAGR of 24.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Psychiatric Digital Biomarkers market.

Global Psychiatric Digital Biomarkers Market - Key Trends & Drivers Summarized

Why Are Psychiatric Digital Biomarkers Revolutionizing Mental Health Diagnostics?

The emergence of psychiatric digital biomarkers is transforming the landscape of mental health diagnostics by providing objective, quantifiable measures for psychiatric disorders. Traditional diagnostic methods for mental health conditions such as depression, anxiety, schizophrenia, and bipolar disorder rely heavily on subjective patient assessments and clinician interpretations. This lack of objective measurement has contributed to delayed diagnoses, ineffective treatments, and inconsistent monitoring of disease progression. Psychiatric digital biomarkers, derived from passive and active data collection methods such as smartphone usage patterns, voice recordings, sleep tracking, facial expressions, and physiological signals, offer a groundbreaking solution to these challenges. With advances in artificial intelligence and machine learning, these biomarkers can identify subtle behavioral and cognitive patterns that may indicate early-onset psychiatric conditions. The growing adoption of wearable technology, mobile health applications, and telemedicine has further accelerated the integration of psychiatric digital biomarkers into clinical practice, enabling real-time mental health monitoring and personalized treatment interventions.

How Are AI and Machine Learning Enhancing Digital Biomarker Accuracy?

The application of artificial intelligence (AI) and machine learning algorithms in psychiatric digital biomarker research has significantly improved the accuracy and predictive power of mental health assessments. AI-driven analytics can process vast amounts of data from multiple sources, detecting patterns and correlations that human clinicians might overlook. For instance, sentiment analysis of voice recordings can identify emotional distress, while keystroke dynamics and speech cadence changes can indicate cognitive decline or depressive states. Advanced machine learning models can also integrate physiological data such as heart rate variability and sleep cycle irregularities to provide a more comprehensive view of a patient's mental health status. As AI models continue to evolve, their ability to refine diagnostic precision and predict psychiatric episodes will likely increase, making digital biomarkers an essential tool for early intervention and treatment optimization. The integration of AI-based mental health tools into existing healthcare infrastructures is paving the way for large-scale adoption, bridging the gap between traditional psychiatry and digital therapeutics.

What Factors Are Driving the Adoption of Digital Biomarkers in Psychiatry?

The increasing prevalence of mental health disorders worldwide, combined with the demand for accessible and scalable diagnostic tools, has fueled the adoption of psychiatric digital biomarkers. The rise of digital health initiatives and the shift toward remote patient monitoring have further strengthened the market, as clinicians seek non-invasive, cost-effective solutions for tracking psychiatric conditions. The COVID-19 pandemic highlighted the need for virtual mental health solutions, accelerating the development and deployment of AI-driven diagnostic platforms and mental health apps. Additionally, regulatory bodies are recognizing the potential of digital biomarkers, with initiatives aimed at standardizing their use in clinical trials and therapeutic monitoring. The integration of psychiatric digital biomarkers into clinical workflows is also being supported by growing investment in digital health startups, partnerships between tech companies and healthcare providers, and the expansion of precision psychiatry initiatives.

What Are the Key Drivers Shaping the Psychiatric Digital Biomarkers Market?

The growth in the global psychiatric digital biomarkers market is driven by several factors, including the increasing burden of mental health disorders, advancements in AI-driven diagnostics, and the widespread adoption of wearable technology. The expansion of telemedicine and remote healthcare solutions has created a conducive environment for digital biomarkers to become mainstream in psychiatric care. The rising acceptance of mobile health applications for mental health self-assessment and intervention has also contributed to market growth. Government initiatives promoting digital health innovation, along with growing insurance coverage for mental health treatments, are further accelerating adoption. Additionally, the increasing demand for personalized medicine and precision psychiatry is fueling research into biomarker-driven treatment strategies, ensuring that digital biomarkers will continue to shape the future of psychiatric healthcare.

Scope of Study:

The report analyzes the Psychiatric Digital Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

• Segments: Type (Wearable, Mobile-based Applications, Sensors, Others); Clinical Practice (Diagnostic Psychiatric Digital Biomarkers, Monitoring Psychiatric Digital Biomarkers, Predictive & Prognostic Psychiatric Digital Biomarkers, Others); End-Use (Healthcare companies, Healthcare Providers, Payers, Others)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Wearable segment, which is expected to reach US$1.1 Billion by 2030 with a CAGR of a 25.7%. The Mobile-based Applications segment is also set to grow at 24.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $166.9 Million in 2024, and China, forecasted to grow at an impressive 32.1% CAGR to reach $547.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Psychiatric Digital Biomarkers Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Psychiatric Digital Biomarkers Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Psychiatric Digital Biomarkers Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as ActiGraph LLC, Adherium Limited, AliveCor Inc., Altoida Inc., Amgen Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Psychiatric Digital Biomarkers market report include:

• ActiGraph LLC
• Adherium Limited
• AliveCor Inc.
• Altoida Inc.
• Amgen Inc.
• Aural Analytics
• Behavidence
• Biogen Inc.
• Brainomix
• Clario
• Earkick
• Empatica Inc.
• Encrypgen
• Feel Therapeutics
• Healthereum
• HIVE Blockchain Technologies Ltd.
• Huma
• Imagene AI
• IXICO plc
• Kinsa Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.